Company: LRHC
Filing Date: 2025-07-17
Form Type: 424B3
Source: 0001213900-25-065175
Chunk: 9

Company: La Rosa Holdings Corp.
Filing Date: 2025-07-17
Form: 424B3
Chunk 9
---
 the Company’s issued and outstanding common stock at a price less
than the minimum price required by the Nasdaq in accordance with Nasdaq Listing Rules 5635(b) and 5635(d); (ii) authorization to complete
a reverse split of our common stock; and (iii) authorization to increase the number of authorized shares of our common stock to ensure
that the Company has a sufficient number of authorized shares reserved for issuance to equal at least 200% of the maximum number of shares
issuable upon conversion of the Notes, as determined under the Securities Purchase Agreement. Such approval was effective on March 27,
2025, or 20 days after commencement of mailing of the definitive information statement regarding this approval to the stockholders of
the Company.

<div align='center'>2</div>

On June 18, 2025, with the prior approval
by the Company’s Board of Directors, the Company and the 2025 Investor entered into, and closed the transactions contemplated by,
that certain Amendment and Exchange Agreement (the “Exchange Agreement”) pursuant to which (among other things) the 2025
Investor surrendered and exchanged all of its Incremental Warrants in exchange for (the “Exchange”) 6,000 shares of the Company’s
Series B Convertible Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”). On the same date, the Company
filed a Certificate of Designation of Rights and Preferences of the Series B Preferred Stock (the “Certificate of Designation”)
with the Secretary of State of the State of Nevada. The Initial Note remains outstanding post-Exchange.

On June 26, 2025, the Company and 2025 Investor
signed an Amendment No. 1 to the Initial Note to correct an administrative error in the definition of maturity date and alternate conversion
price in the Initial Note.

Pursuant to the terms of the Exchange Agreement,
conversion of the Series B Preferred Stock into shares of common stock of the Company in excess of 19.99% of the Company’s outstanding
shares of common stock is conditional upon obtaining the approval of the Company’s stockholders in accordance with the rules and
regulations of the Nasdaq Capital Market. The Company agreed to convene a meeting of stockholders to obtain such approval within 120
days after the date of the Exchange Agreement.

Third Amended Agent Plan

On February 4, 2025, the Compensation Committee,
our Board of Directors, and the majority stockholders